AMGN

Amgen's stock price has experienced fluctuations in the past six months, with a 50.12% increase over the previous year, reaching $423.64 as of September 29, 2026. On June 25, 2026, shares increased to an 11-week high of $358.73. However, on September 8, 2026, Amgen's shares fell 10% to $407.08, the lowest since August 2026, following news that a cardiovascular drug trial by Novartis and Ionis did not reduce key cardiovascular events. Positive news included FDA approval for reduced monitoring time for IMDELLTRA® on September 14, 2026, and positive topline Phase 3 results for dazodalibep in systemic Sjögren's disease announced on September 22, 2026. News on September 28, 2026, about the KRAS Inhibitor Market's projected growth could be relevant to Amgen's oncology pipeline. For Q2 2026, Amgen reported strong results with total revenues exceeding $10 billion, a 10% year-over-year increase, and raised its full-year guidance, driven by strong volume demand and double-digit sales growth for 22 products, including Repatha (37%), EVENITY (38%), and TEZSPIRE (42%), despite a 33% decrease in Prolia and XGEVA sales due to biosimilar competition. Amgen is scheduled to release its next earnings report on November 3, 2026.